Last reviewed · How we verify

NCT04296110

Impact of a Biofeedback Intervention on Microbiome, Metabolome, and Clinical Outcomes in Pediatric IBD (Study 2)

Terminated NA Last updated 15 August 2024
What this trial tests

NA trial testing Biofeedback in IBD in 48 participants. Terminated before completion.

Timeline
12 March 2020
Primary endpoint
14 August 2024
14 August 2024

Quick facts

Lead sponsorNationwide Children's Hospital
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment48
Start date12 March 2020
Primary completion14 August 2024
Estimated completion14 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Nationwide Children's Hospital

Who can join

Adults 8 to 17, any sex, with IBD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, randomized, longitudinal, controlled study will enroll pediatric CD patients with inflammatory, non-stricturing, and non-penetrating disease type with mild/quiescent disease based on Pediatric Crohn's Disease Activity Index (PCDAI). Participants will be randomized to receive HRV biofeedback intervention daily for 12 weeks or to music relaxation therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Biofeedback

Trials testing the same drug.

Other recruiting trials for IBD

Currently open trials in the same condition.

Other Nationwide Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04296110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing